The synthesis of dihydrotestosterone is catalyzed by steroid 5a-reductase isozymes, designated types 1 and 2. Mutation of type 2 results in male pseudohermaphroditism, in which the external genitalia are phenotypically female at birth. Two striking and unexplained features of this disorder are that external genitalia of affected males undergo virilization during puberty and that these individuals have less temporal hair regression. The tissue-specific and developmental expression patterns of the 5a-reductase isozymes were investigated by immunoblotting. The type 1 isozyme is not detectable in the fetus, is transiently expressed in newborn skin and scalp, and permanently expressed in skin from the time of puberty. There was no qualitative difference in 5a-reductase type 1 expression between adult balding vs. nonbalding scalp. The type 2 isozyme is transiently expressed in skin and scalp of newborns. Type 2 is the predominant isozyme detectable in fetal genital skin, male accessory sex glands, and in the prostate, including benign prostatic hyperplasia and prostate adenocarcinoma tissues. Both isozymes are expressed in the liver, but only after birth. These results are consistent with 5a-reductase type 1 being responsible for virilization in type 2-deficient subjects during puberty, and suggest that the type 2 isozyme may be an initiating factor in development of male pattern baldness. (J. Clin. Invest. 1993. 92:903-910.) Key words: dihydrotestosterone* sexual differentiation * benign prostatic hyperplasia* prostate cancer * male pattern baldness
Introduction
Alterations in the conversion of testosterone into dihydrotestosterone by the enzyme steroid 5a-reductase (5a-reductase, E.C. 1.3.99.5) are associated with a number of human disorders. Decreased synthesis of dihydrotestosterone due to mutations in the 5a-reductase gene results in affected 46,XY males being born with normal internal reproductive structures (epididymes, seminal vesicles, and vasa deferentia), but with external genitalia that resemble those ofthe female and a prostate that is hypoplastic (1) (2) (3) . Strikingly, and for unknown reasons, virilization of the external genitalia occurs to varying extents in affected individuals during puberty (3, 4) , although secondary sexual hair remains sparse and they develop less male pattern baldness and acne (25) .
The reduced temporal hair regression in 5a-reductase-deficient individuals suggests that the synthesis ofdihydrotestosterone may contribute to this frequent and characteristic male affliction (6) . In support of this notion, earlier studies show that 5a-reductase enzyme activity is increased in hair follicles of balding scalp but not in nonbalding scalp (7, 8) . Interestingly, 5a-reductase enzyme activity is normal in hair follicles of subjects with 5a-reductase deficiency (9) .
The recent isolation of two functional genes encoding different isozymes of 5a-reductase in the human and rat provides an explanation for why these subjects have normal levels of enzyme activity in their hair follicles (10) (11) (12) (13) . The 5a-reductase type 1 gene (SRD5AJ) encodes an isozyme with an alkaline pH optimum (14, 15) , whereas the 5a-reductase type 2 gene (SRD5A2) encodes an isozyme with an acidic pH optimum ( 12, 16) . The two 5a-reductase isozymes can also be distinguished by their 4-azasteroid inhibitor pharmacologies ( 12, 17) . Little is known about the relative tissue distribution and developmental expression patterns ofthe two 5a-reductase isozymes. No genetic deficiencies ofthe type 1 enzyme have yet been reported. Mutations in the type 2 gene underlie classical 5a-reductase deficiency (12, 16, 18) , and the type 1 gene is normal in these subjects (14) .
An increased synthesis ofdihydrotestosterone may contribute to the development of benign and neoplastic growth of the prostate in aging males. In benign prostatic hyperplasia (BPH),' an increase in the organ content of dihydrotestosterone has been noted in some ( 19) but not all studies (20) . Administration of a selective inhibitor of 5a-reductase type 2 (the 4-azasteroid finasteride) has been shown to result in a decrease in prostate volume in some men with BPH (21, 22) . The level of 5a-reductase enzyme activity has been reported to be higher in prostate tumors in some (23) , but not all studies (24, 25) .
To gain insight into the physiological roles of each of the two 5a-reductase isozymes in normal and pathological states, we investigated the tissue distribution and relative expression of each isozyme during human development.
Methods
Antibodies. Polyclonal antipeptide antibodies were prepared following standard protocols in New Zealand White rabbits (26) . A peptide representing amino acids 232 to 256 ofthe 5a-reductase type 1 isozyme ( 11 ) was synthesized and coupled to keyhole lympet hemocyanin with mmaleimidobenzoic acid N-hydroxysuccinimide ester. A peptide representing amino acids 227 to 251 of the type 2 isozyme ( 12) was used as an antigen directly without coupling. Rabbits were injected subdermally with the conjugate or the free peptide and Freund's complete adjuvant as described (27) . Antisera were collected after injection and tested by immunoblotting for their ability to recognize the 5a-reductase isozymes in cell lysates derived from permanent Chinese hamster ovary (CHO) cell lines expressing individual 5a-reductase cDNAs (CHO-1827, type 1 cDNA; CHO-1829, type 2 cDNA). Affinity purification of the antipeptide sera was done according to standard procedures (26 mM Tris, pH 7.5,14 mM NaCl, 3 mM KC1(TBS) containing 10% (wt/vol) powdered milk and 0.2% (vol/vol) Tween-20. 5a-Reductase antisera were diluted 1 in 1,000 in TBS with powdered milk, Tween-20, and 0.5% (vol/vol) NP-40 and incubated with the filters at 220C for 2-3 h. The filters were washed three times for 10 min in TBS containing 0.1% (wt/vol) SDS, 1% (vol/vol) NP-40, and 0.5% (wt/vol) deoxycholate prior to addition ofa 1 in 2,000 dilution of a donkey anti-rabbit IgG serum coupled to horseradish peroxidase (Amersham Corp., Arlington Heights, IL). The second antibody was incubated with the filter for 20 min followed by three washes in the above buffer. Immune complexes were visualized by incubation with substrates for chemiluminescence detection (Amersham Corp.) for 1 min. Filters were exposed to x-ray film for 2 to 8 min.
Results
Antipeptide antibodies directed against the carboxy-termini of the type 1 and type 2 isozymes of Sa-reductase were generated in rabbits. Lysates prepared from CHO cell lines expressing either the type 1 As indicated by the asterisks in Fig. 1 A, the type 1 isozyme was detected in the liver and chest skin. Several tissues contained proteins distinct from 5a-reductase that were recognized by the polyclonal antibodies (e.g., kidney, Fig. 1 A) .
With the exception of the pituitary gland, the molecular weights of these other proteins were substantially larger than that of the type 1 enzyme (M, = 23,000). The inclusion of antigenic peptide (7 ,g/ml) in the immunoblotting reaction abolished recognition of only the type 1 isozyme (Fig. 1 B) . The recognition of the pituitary protein with a molecular weight slightly smaller than that of 5a-reductase type 1 was not affected by inclusion of peptide ( Fig. 1 B) . The 5a-reductase type 2 isozyme was detected in the epididymis, seminal vesicle, prostate, and liver ( Fig. 2 A, asterisks) . As with the type 1 antibodies, several high molecular weight proteins were detected in the different tissues, but the recognition of these proteins was not abolished by inclusion of the antigenic peptide (7 gug/ml), whereas recognition ofthe type 2 isozyme was ( Fig. 2 B) . The results shown in Figs. 1 and 2 are representative of those obtained in surveys of tissues derived from five individuals. To confirm and extend the results obtained in the immunoblotting experiments, the levels of 5a-reductase isozyme mRNA ( Fig. 3 ) and activity (Table I) were determined in these tissues. Type 1 mRNAs of 7.5 and 2.4 kilobases (kb) were detected in the cerebellum, hypothalamus, medulla oblongata, pons, and liver ( Fig. 3 A) . No type 1 mRNA was detected in the kidney (Fig. 3 A) . Hybridization of the filter with a control cyclophilin cDNA probe revealed the presence of mRNA in all lanes of the blot (Fig. 3 A, lower autoradiogram) .
Hybridization with 5a-reductase type 2 cDNA probes revealed mRNAs of 2.4 and 4.4 kb in the epididymis, liver, prostate, and seminal vesicles (Fig. 3 B) . A cyclophilin mRNA of 0.8 kb was detected in all tissues (Fig. 3 B, lower autoradiogram) . In experiments not shown, no type 2 mRNA was detected in the medulla oblongata or pituitary. The overall RNA blotting results are representative of six different experiments.
5a-reductase enzyme activity in tissue homogenates was determined at pH 7.0 (type 1 isozyme optimum) and at pH 5.0 (type 2 isozyme optimum). As indicated in Table I moderate enzyme activity was detected at pH 7.0 in all tissues except skeletal muscle and testis. Enzyme activity was detected at pH 5.0 in all tissues except skeletal muscle, adrenal, hypothalamus, and pons. Because the pH activity profiles of the two isozymes overlap considerably ( 12), the relative contributions ofthe two isozymes to these activities were estimated by calculating the ratio of pH 7.0/pH 5.0 activity (Table I) . Tissues with a pH 7.0/pH 5.0 ratio ofless than 1.0, such as the prostate, seminal vesicle, epididymis, and medulla oblongata appear to express predominantly 5a-reductase type 2 (pH 5.0 optimum), whereas tissues that have a ratio greater than 1.0 express more type 1 isozyme (pH 7.0 optimum). A striking finding demonstrated by these enzyme activity measurements is the lack of correlation between the steady state mRNA levels encoding the type 1 isozyme and the level of enzyme activity. For example, although the level of type 1 mRNA in the hypothalamus is higher than that in skin (Fig. 3 A) , the skin contains 1,400 times more enzyme activity at pH 7.0 than the hypothalamus (Table I ). This result is confirmed by the immunoblotting results. In contrast, the levels of type 2 mRNA and pH 5.0 enzyme activity correlate quite well. In addition to the tissue distribution studies, the ontogeny of 5a-reductase isozyme expression was examined by immunoblotting. A preliminary survey ofseven fetal tissues (liver, adrenal, testis, ovary, brain, scalp, chest skin, and genital skin) derived from males and females of gestational ages of 12. The expression patterns of the two 5a-reductase isozymes in the tissues of newborns were surveyed next. As shown in the upper panel of Fig. 4 , the type 1 isozyme was detected in the liver, and in the skin and scalp of newborns. The type 2 isozyme was detected in the liver, prostate, seminal vesicle, and epididymis, and was also present in the skin and scalp (Fig. 4,  lowerpanel) . The recognition ofboth isozymes by their respective antisera was abolished by inclusion of antigenic peptide in the immunoblotting reactions (Fig. 4 , panels labeled "+ Peptide").
Tissue extracts from the liver, skin, and prostate of adolescents and adults were next prepared and subjected to immunoblotting. The data in the upper panel of Fig. 5 indicate that 5a-reductase type 1 is absent from fetal liver but is detectable in this organ at age 7, 21, and 62 yr. Surprisingly, this isozyme is not present in prepubertal chest skin, but is expressed in this organ in postpubertal individuals (21 and 62 yr of age). The type 1 isozyme could not be detected in prostate at any age (Fig. 5, upper panel) . Preincubation of the type 1 antiserum with the peptide antigen completely abolished recognition of this isozyme in liver, skin, and transfected CHO cell lysates (Fig. 5, upper panel labeled "+ Peptide").
The type 2 isozyme showed a similar expression pattern in the liver, being absent in the fetal organ but present at ages 7, 21, and 62 yr (Fig. 5, lower panel) . This isozyme could not be detected in any of the chest skin samples, but was present in all of the prostate samples. The recognition of the type 2 isozyme (but not cross-reacting proteins) by the antiserum was blocked by incubation in the presence of the antigenic peptide (Fig. 5 , lower panel lanes labeled "+ Peptide").
The qualitative data of Fig. 6 summarize the developmental expression patterns ofthe two 5a-reductase isozymes in the liver, skin, and scalp. In all, 27 liver samples and 24 skin and scalp samples were analyzed from individuals ranging in age from 12.7-wk gestation to 81 yr. In the liver, the two isozymes had an identical temporal pattern of expression (Fig. 6, upper  panel) , whereas in the skin the two isozymes differed in their expression patterns (Fig. 6, lowerpanel) . Both were detected in the neonate, but only the type 2 isozyme was detected in the skin and scalp of a 1.6-and a 3.0-yr-old individual. However, the level of type 2 expression in these two individuals was less than that in younger newborns. From age 15 through adulthood, only the type 1 isozyme was detected in the skin and scalp samples (Fig. 6, lower panel) .
The expression patterns of the 5a-reductase isozymes were next analyzed in three common (Fig. 7 , rightmost two lanes). The different molecular weights of the two isozymes however (type 1 > type 2), allows for differentiation of reaction from cross-reaction.
To examine Sa-reductase isozyme expression in male pattern baldness, seven segments ( -1 cm2 each) were taken from a 51 yr-old Caucasian male with Hamilton type VIII baldness (6) . The seven segments formed an arbitrary gradient from the crown (-4) to the hairline (0) to the peripheral region (+2) of the scalp (Fig. 8 ). Extracts were prepared from each segment (Fig. 9, upperpanel) and five unrelated extensively balding individuals (Fig. 9 , lower panel) were subjected to immunoblotting with the anti-type 1 sera. With one exception, the levels of Sa-reductase type 1 did not differ dramatically between these individuals, or between regions of the scalp with or without hair.
The exception was a slightly balding individual (AT 14, reduction appeared to be specific for the5a-reductase isozyme, as the levels ofcross-reacting proteins were not diminished relative to other individuals. The level of the type 1 isozyme was similarly decreased in the liver of subject AT14 (data not shown). The basis for the decreased type 1 expression in these organs is not known, however unlike the other individuals, subject AT14 was very obese (> 400 lbs) and it is conceivable that this condition contributed to the finding. In other experiments, the expression of 5a-reductase type 1 in female scalp was qualitatively equivalent to that of male scalp (summarized in Fig. 7 ), a result that agrees with previous enzyme activity measurements (8) .
Discussion
In this paper we describe the tissue specific and ontological expression patterns of two 5a-reductase isozymes. (30) .
Among postnatal tissues, the type 2 isozyme was detected by immunoblotting in the liver, prostate, seminal vesicle, and epididymis (Figs. 2 and 3) . Expression in the liver appears to commence at birth (Fig. 6) . (The actual window of this induction period is between 19 weeks of gestational age and 2 months [ Fig. 6]) . In contrast, induction in the genital tract occurs in the embryo (30) . The physiologic role of Sa-reductase type 2 in tissues other than the prostate and anlagen of the external genitalia remains unknown, since these organs do not appear to be affected by the genetic absence of this isozyme or by its pharmacologic inhibition (21, 22) . Furthermore, women who inherit two mutations in the type 2 gene have normal sexual development and are fertile (4) .
An intriguing feature of5a-reductase type 2 deficiency has been the observation that affected individuals virilize to different extents during puberty (3) (4) (5) . Masculinization occurs regardless of the type of mutation present in the SRD5A2 gene, i.e., both in subjects with a complete deletion of the gene, and hence no residual type 2 activity, and in subjects with only qualitative defects in the enzyme (16, 18) . Two findings reported here are consistent with a role for the5a-reductase type 1 isozyme in the observed virilization. First, the expression of this isozyme begins at or near birth in the liver and continues throughout life in this organ (Fig. 6) . Second, the synthesis of the type 1 isozyme is induced at or during puberty in the skin and scalp and continues thereafter (Figs. 6, 8, 9 ). Given the large contribution of the skin and liver to relative body mass (-25%), it is reasonable to assume that the production of dihydrotestosterone by these organs at puberty drives virilization of the external genitalia and influences the pattern of hair distribution in type 2-deficient subjects. If this hypothesis is correct, then dihydrotestosterone can act in a true endocrine fashion as well as by the autocrine or paracrine mechanisms typically ascribed to this hormone (3). Two clinical observations support this hypothesis. First, individuals with a complete deletion of the type 2 gene (12) can have serum dihydrotestosterone levels within the normal range (5) . Second, the administration oftestosterone to an individual with a splicing mutation in the type 2 gene results in normal serum dihydrotestosterone levels (31 ) . These results also suggest that the effective treatment of diseases such as BPH that are caused in part by the action of dihydrotestosterone will require pharmacological inhibition of bothSa-reductase isozymes.
Two recent studies also support the expression of Sa-reductase in adult skin. Harris et al. characterized aSa-reductase activity in scalp with the biochemical and pharmacological properties of the type 1 isozyme (32). Imperato-McGinley and colleagues further showed that sebum production, an androgen-dependent process, in subjects with complete androgen insensitivity was undetectable, whereas production inSa-reductase type 2 deficient subjects was normal (33 A surprising finding in the current studies is the oscillating expression of both 5a-reductase isozymes in the skin and scalp during development (Fig. 6) . Analysis of 24 individuals ranging from 12.7 wk of gestational age to 81 yr, revealed that both Sa-reductase genes are induced in this organ at birth and continue to be expressed until -2-3 yr of age. Thereafter, the expression ofboth is extinguished until puberty, at which time the type 1 isozyme, but not the type 2 isozyme, is induced in the skin and scalp (Fig. 6) In support of this speculation regarding type 2 expression, we could find no qualitative differences in the steady state levels of 5a-reductase type 1 in the scalps of balding and nonbalding men (Fig. 9 ), nor were any regional expression differences detected in the balding scalp (Fig. 8) (Fig. 3, Table I )), nor can we assess changes in cell type specific expression. It remains to be seen whether similar results will be obtained in hirsutism (35, 36) and acne (37) , two disorders that are manifest together with the reappearance of Sa-reductase type 1 expression in the skin at puberty.
In the prostate, cell division and glandular growth are dependent on the synthesis of dihydrotestosterone (3). In both the normal prostate and in the two most common pathological conditions of this gland, BPH and prostate cancer, the type 2 isozyme appears to be responsible for this dihydrotestosterone synthesis (Figs. 2, 4, 5, 7 ). This result was somewhat surprising because mRNA for the type 1 isozyme is readily detected in the prostate (reference 1, Fig. 3 ). However, very little type 1 enzyme activity is present in prostate extracts, suggesting that the mRNA may be poorly translated (14) , a hypothesis amply confirmed by major discrepancies between type 1 enzyme activity and mRNA levels in other tissues (Fig. 3 , Table I ). In BPH, the proliferation of both epithelial and stromal cells typically underlies the benign growth of the gland that may eventually lead to obstruction ofthe urethra (38 Russell, unpublished observations). These disparate expression patterns suggest that the two isozymes may be differentially regulated and therefore serve different physiological functions in the human and the rat.
